nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Dactinomycin—germ cell cancer	0.122	0.274	CbGbCtD
Afatinib—ABCG2—Cisplatin—germ cell cancer	0.0699	0.158	CbGbCtD
Afatinib—ABCG2—Etoposide—germ cell cancer	0.0686	0.155	CbGbCtD
Afatinib—ABCG2—Methotrexate—germ cell cancer	0.0453	0.102	CbGbCtD
Afatinib—ABCB1—Dactinomycin—germ cell cancer	0.0439	0.099	CbGbCtD
Afatinib—ABCB1—Vinblastine—germ cell cancer	0.0275	0.062	CbGbCtD
Afatinib—ABCB1—Cisplatin—germ cell cancer	0.0252	0.0568	CbGbCtD
Afatinib—ABCB1—Etoposide—germ cell cancer	0.0247	0.0559	CbGbCtD
Afatinib—Mucosal ulceration—Ifosfamide—germ cell cancer	0.0215	0.128	CcSEcCtD
Afatinib—ABCB1—Methotrexate—germ cell cancer	0.0164	0.0369	CbGbCtD
Afatinib—Pulmonary toxicity—Ifosfamide—germ cell cancer	0.00681	0.0406	CcSEcCtD
Afatinib—Pulmonary toxicity—Cisplatin—germ cell cancer	0.00587	0.035	CcSEcCtD
Afatinib—ERBB2—Podofilox—Etoposide—germ cell cancer	0.00522	1	CbGdCrCtD
Afatinib—Paronychia—Methotrexate—germ cell cancer	0.00422	0.0251	CcSEcCtD
Afatinib—Cheilitis—Dactinomycin—germ cell cancer	0.00397	0.0237	CcSEcCtD
Afatinib—Mucosal inflammation—Bleomycin—germ cell cancer	0.00327	0.0195	CcSEcCtD
Afatinib—ERBB2—neck—germ cell cancer	0.00327	0.0202	CbGeAlD
Afatinib—Pulmonary toxicity—Methotrexate—germ cell cancer	0.00322	0.0192	CcSEcCtD
Afatinib—Mucosal inflammation—Ifosfamide—germ cell cancer	0.00279	0.0166	CcSEcCtD
Afatinib—PHKG2—brainstem—germ cell cancer	0.00278	0.0172	CbGeAlD
Afatinib—ERBB2—embryo—germ cell cancer	0.00272	0.0168	CbGeAlD
Afatinib—ERBB4—embryo—germ cell cancer	0.00272	0.0168	CbGeAlD
Afatinib—HIPK4—gonad—germ cell cancer	0.0027	0.0167	CbGeAlD
Afatinib—Interstitial lung disease—Bleomycin—germ cell cancer	0.00256	0.0152	CcSEcCtD
Afatinib—ERBB4—brainstem—germ cell cancer	0.0025	0.0154	CbGeAlD
Afatinib—DYRK1A—brainstem—germ cell cancer	0.0024	0.0149	CbGeAlD
Afatinib—BLK—adrenal gland—germ cell cancer	0.00235	0.0145	CbGeAlD
Afatinib—ERBB4—telencephalon—germ cell cancer	0.00222	0.0137	CbGeAlD
Afatinib—Mucosal inflammation—Etoposide—germ cell cancer	0.00221	0.0131	CcSEcCtD
Afatinib—Interstitial lung disease—Ifosfamide—germ cell cancer	0.00218	0.013	CcSEcCtD
Afatinib—DYRK1A—telencephalon—germ cell cancer	0.00213	0.0132	CbGeAlD
Afatinib—EPHA6—gonad—germ cell cancer	0.00213	0.0132	CbGeAlD
Afatinib—ERBB2—skin of body—germ cell cancer	0.00211	0.0131	CbGeAlD
Afatinib—ERBB2—decidua—germ cell cancer	0.0021	0.013	CbGeAlD
Afatinib—LCK—trigeminal ganglion—germ cell cancer	0.00206	0.0127	CbGeAlD
Afatinib—PHKG2—gonad—germ cell cancer	0.00206	0.0127	CbGeAlD
Afatinib—HIPK4—endocrine gland—germ cell cancer	0.00204	0.0126	CbGeAlD
Afatinib—DYRK1A—decidua—germ cell cancer	0.00202	0.0125	CbGeAlD
Afatinib—HIPK4—testis—germ cell cancer	0.00194	0.012	CbGeAlD
Afatinib—PHKG2—medulla oblongata—germ cell cancer	0.00194	0.012	CbGeAlD
Afatinib—EGFR—telencephalon—germ cell cancer	0.00188	0.0116	CbGeAlD
Afatinib—ERBB2—gonad—germ cell cancer	0.00185	0.0114	CbGeAlD
Afatinib—ERBB2—uterus—germ cell cancer	0.00184	0.0114	CbGeAlD
Afatinib—ERBB4—pituitary gland—germ cell cancer	0.0018	0.0111	CbGeAlD
Afatinib—PHKG2—adrenal gland—germ cell cancer	0.00179	0.0111	CbGeAlD
Afatinib—DYRK1A—gonad—germ cell cancer	0.00178	0.011	CbGeAlD
Afatinib—Cystitis noninfective—Bleomycin—germ cell cancer	0.00177	0.0105	CcSEcCtD
Afatinib—Cystitis—Bleomycin—germ cell cancer	0.00175	0.0104	CcSEcCtD
Afatinib—ERBB4—medulla oblongata—germ cell cancer	0.00174	0.0108	CbGeAlD
Afatinib—Interstitial lung disease—Etoposide—germ cell cancer	0.00173	0.0103	CcSEcCtD
Afatinib—PHKG2—female gonad—germ cell cancer	0.00167	0.0103	CbGeAlD
Afatinib—IRAK1—telencephalon—germ cell cancer	0.00166	0.0102	CbGeAlD
Afatinib—Rhinorrhoea—Cisplatin—germ cell cancer	0.00165	0.00981	CcSEcCtD
Afatinib—Bladder pain—Bleomycin—germ cell cancer	0.00164	0.00975	CcSEcCtD
Afatinib—EPHA6—endocrine gland—germ cell cancer	0.00161	0.00996	CbGeAlD
Afatinib—ERBB2—adrenal gland—germ cell cancer	0.00161	0.00996	CbGeAlD
Afatinib—EPHA6—head—germ cell cancer	0.00159	0.00983	CbGeAlD
Afatinib—ERBB4—midbrain—germ cell cancer	0.00159	0.00983	CbGeAlD
Afatinib—IRAK1—decidua—germ cell cancer	0.00157	0.00971	CbGeAlD
Afatinib—EGFR—uterus—germ cell cancer	0.00156	0.00963	CbGeAlD
Afatinib—PHKG2—endocrine gland—germ cell cancer	0.00155	0.00961	CbGeAlD
Afatinib—ERBB4—spinal cord—germ cell cancer	0.00155	0.00959	CbGeAlD
Afatinib—DYRK1A—adrenal gland—germ cell cancer	0.00155	0.00959	CbGeAlD
Afatinib—EPHA6—testis—germ cell cancer	0.00154	0.0095	CbGeAlD
Afatinib—PHKG2—head—germ cell cancer	0.00153	0.00948	CbGeAlD
Afatinib—LCK—decidua—germ cell cancer	0.00153	0.00947	CbGeAlD
Afatinib—Mouth ulceration—Dactinomycin—germ cell cancer	0.00153	0.00909	CcSEcCtD
Afatinib—ERBB2—female gonad—germ cell cancer	0.0015	0.00929	CbGeAlD
Afatinib—PHKG2—testis—germ cell cancer	0.00148	0.00916	CbGeAlD
Afatinib—Sepsis—Dactinomycin—germ cell cancer	0.00146	0.00873	CcSEcCtD
Afatinib—HIPK4—brain—germ cell cancer	0.00146	0.00902	CbGeAlD
Afatinib—DYRK1A—female gonad—germ cell cancer	0.00145	0.00894	CbGeAlD
Afatinib—BLK—lymph node—germ cell cancer	0.00141	0.00871	CbGeAlD
Afatinib—ERBB2—endocrine gland—germ cell cancer	0.0014	0.00864	CbGeAlD
Afatinib—ERBB4—endocrine gland—germ cell cancer	0.0014	0.00864	CbGeAlD
Afatinib—ERBB4—head—germ cell cancer	0.00138	0.00853	CbGeAlD
Afatinib—ERBB2—head—germ cell cancer	0.00138	0.00853	CbGeAlD
Afatinib—PHKG2—cerebellum—germ cell cancer	0.00137	0.00846	CbGeAlD
Afatinib—EGFR—adrenal gland—germ cell cancer	0.00137	0.00844	CbGeAlD
Afatinib—DYRK1A—endocrine gland—germ cell cancer	0.00134	0.00831	CbGeAlD
Afatinib—Sepsis—Ifosfamide—germ cell cancer	0.00134	0.008	CcSEcCtD
Afatinib—LCK—uterus—germ cell cancer	0.00134	0.00828	CbGeAlD
Afatinib—ERBB2—testis—germ cell cancer	0.00133	0.00824	CbGeAlD
Afatinib—ERBB4—testis—germ cell cancer	0.00133	0.00824	CbGeAlD
Afatinib—DYRK1A—head—germ cell cancer	0.00133	0.00821	CbGeAlD
Afatinib—Mucosal inflammation—Methotrexate—germ cell cancer	0.00132	0.00787	CcSEcCtD
Afatinib—DYRK1A—testis—germ cell cancer	0.00128	0.00793	CbGeAlD
Afatinib—EGFR—female gonad—germ cell cancer	0.00127	0.00787	CbGeAlD
Afatinib—ERBB2—cerebellum—germ cell cancer	0.00123	0.00761	CbGeAlD
Afatinib—ERBB4—cerebellum—germ cell cancer	0.00123	0.00761	CbGeAlD
Afatinib—IRAK1—adrenal gland—germ cell cancer	0.00121	0.00745	CbGeAlD
Afatinib—IRAK1—midbrain—germ cell cancer	0.00119	0.00736	CbGeAlD
Afatinib—DYRK1A—cerebellum—germ cell cancer	0.00118	0.00732	CbGeAlD
Afatinib—ABL1—trigeminal ganglion—germ cell cancer	0.00118	0.00731	CbGeAlD
Afatinib—Renal impairment—Ifosfamide—germ cell cancer	0.00118	0.00703	CcSEcCtD
Afatinib—LCK—adrenal gland—germ cell cancer	0.00118	0.00727	CbGeAlD
Afatinib—IRAK1—bone marrow—germ cell cancer	0.00117	0.00721	CbGeAlD
Afatinib—EPHA6—brain—germ cell cancer	0.00115	0.00713	CbGeAlD
Afatinib—ABL1—embryo—germ cell cancer	0.00114	0.00705	CbGeAlD
Afatinib—LCK—bone marrow—germ cell cancer	0.00114	0.00703	CbGeAlD
Afatinib—EGFR—testis—germ cell cancer	0.00113	0.00698	CbGeAlD
Afatinib—IRAK1—female gonad—germ cell cancer	0.00112	0.00695	CbGeAlD
Afatinib—PHKG2—brain—germ cell cancer	0.00111	0.00687	CbGeAlD
Afatinib—Mouth ulceration—Etoposide—germ cell cancer	0.0011	0.00658	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Dactinomycin—germ cell cancer	0.0011	0.00657	CcSEcCtD
Afatinib—LCK—female gonad—germ cell cancer	0.0011	0.00678	CbGeAlD
Afatinib—PHKG2—lymph node—germ cell cancer	0.00107	0.00664	CbGeAlD
Afatinib—Sepsis—Etoposide—germ cell cancer	0.00106	0.00632	CcSEcCtD
Afatinib—ABL1—brainstem—germ cell cancer	0.00105	0.00647	CbGeAlD
Afatinib—EGFR—cerebellum—germ cell cancer	0.00104	0.00645	CbGeAlD
Afatinib—Interstitial lung disease—Methotrexate—germ cell cancer	0.00103	0.00616	CcSEcCtD
Afatinib—Weight decreased—Bleomycin—germ cell cancer	0.00103	0.00612	CcSEcCtD
Afatinib—Hypokalaemia—Ifosfamide—germ cell cancer	0.00102	0.00609	CcSEcCtD
Afatinib—ABL1—eye—germ cell cancer	0.00102	0.00629	CbGeAlD
Afatinib—Pneumonia—Bleomycin—germ cell cancer	0.00102	0.00607	CcSEcCtD
Afatinib—ABL1—retina—germ cell cancer	0.00101	0.00624	CbGeAlD
Afatinib—ERBB4—brain—germ cell cancer	0.001	0.00618	CbGeAlD
Afatinib—ERBB2—brain—germ cell cancer	0.001	0.00618	CbGeAlD
Afatinib—IRAK1—testis—germ cell cancer	0.000997	0.00616	CbGeAlD
Afatinib—Stomatitis—Bleomycin—germ cell cancer	0.000986	0.00588	CcSEcCtD
Afatinib—LCK—testis—germ cell cancer	0.000972	0.00601	CbGeAlD
Afatinib—ERBB2—lymph node—germ cell cancer	0.000966	0.00597	CbGeAlD
Afatinib—DYRK1A—brain—germ cell cancer	0.000962	0.00595	CbGeAlD
Afatinib—Alopecia—Vinblastine—germ cell cancer	0.000951	0.00566	CcSEcCtD
Afatinib—Pneumonia—Dactinomycin—germ cell cancer	0.000949	0.00566	CcSEcCtD
Afatinib—DYRK1A—lymph node—germ cell cancer	0.00093	0.00575	CbGeAlD
Afatinib—ABL1—telencephalon—germ cell cancer	0.000928	0.00574	CbGeAlD
Afatinib—IRAK1—cerebellum—germ cell cancer	0.00092	0.00569	CbGeAlD
Afatinib—Stomatitis—Dactinomycin—germ cell cancer	0.00092	0.00548	CcSEcCtD
Afatinib—Dehydration—Cisplatin—germ cell cancer	0.0009	0.00536	CcSEcCtD
Afatinib—ABL1—skin of body—germ cell cancer	0.000886	0.00548	CbGeAlD
Afatinib—Hypokalaemia—Cisplatin—germ cell cancer	0.000881	0.00525	CcSEcCtD
Afatinib—ABL1—decidua—germ cell cancer	0.00088	0.00544	CbGeAlD
Afatinib—Aspartate aminotransferase increased—Cisplatin—germ cell cancer	0.000871	0.00519	CcSEcCtD
Afatinib—Pneumonia—Ifosfamide—germ cell cancer	0.00087	0.00518	CcSEcCtD
Afatinib—Nasopharyngitis—Cisplatin—germ cell cancer	0.000865	0.00516	CcSEcCtD
Afatinib—Infestation NOS—Ifosfamide—germ cell cancer	0.000865	0.00515	CcSEcCtD
Afatinib—Infestation—Ifosfamide—germ cell cancer	0.000865	0.00515	CcSEcCtD
Afatinib—Renal failure—Ifosfamide—germ cell cancer	0.00085	0.00507	CcSEcCtD
Afatinib—EGFR—brain—germ cell cancer	0.000847	0.00524	CbGeAlD
Afatinib—Stomatitis—Ifosfamide—germ cell cancer	0.000843	0.00502	CcSEcCtD
Afatinib—Conjunctivitis—Ifosfamide—germ cell cancer	0.000841	0.00501	CcSEcCtD
Afatinib—EGFR—lymph node—germ cell cancer	0.000819	0.00506	CbGeAlD
Afatinib—Hepatobiliary disease—Ifosfamide—germ cell cancer	0.000818	0.00487	CcSEcCtD
Afatinib—Alopecia—Bleomycin—germ cell cancer	0.000803	0.00478	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Etoposide—germ cell cancer	0.000782	0.00466	CcSEcCtD
Afatinib—ABL1—gonad—germ cell cancer	0.000775	0.00479	CbGeAlD
Afatinib—ABL1—uterus—germ cell cancer	0.000769	0.00476	CbGeAlD
Afatinib—Urinary tract disorder—Ifosfamide—germ cell cancer	0.000767	0.00457	CcSEcCtD
Afatinib—Connective tissue disorder—Ifosfamide—germ cell cancer	0.000763	0.00455	CcSEcCtD
Afatinib—Urethral disorder—Ifosfamide—germ cell cancer	0.000761	0.00454	CcSEcCtD
Afatinib—ABL1—pituitary gland—germ cell cancer	0.000756	0.00467	CbGeAlD
Afatinib—Alopecia—Dactinomycin—germ cell cancer	0.000749	0.00446	CcSEcCtD
Afatinib—IRAK1—brain—germ cell cancer	0.000748	0.00462	CbGeAlD
Afatinib—ABCG2—trigeminal ganglion—germ cell cancer	0.000745	0.00461	CbGeAlD
Afatinib—Renal failure—Cisplatin—germ cell cancer	0.000733	0.00437	CcSEcCtD
Afatinib—ABL1—medulla oblongata—germ cell cancer	0.000729	0.00451	CbGeAlD
Afatinib—Stomatitis—Cisplatin—germ cell cancer	0.000727	0.00433	CcSEcCtD
Afatinib—Eye disorder—Ifosfamide—germ cell cancer	0.000726	0.00432	CcSEcCtD
Afatinib—Conjunctivitis—Cisplatin—germ cell cancer	0.000725	0.00432	CcSEcCtD
Afatinib—IRAK1—lymph node—germ cell cancer	0.000722	0.00447	CbGeAlD
Afatinib—Cystitis noninfective—Methotrexate—germ cell cancer	0.000714	0.00426	CcSEcCtD
Afatinib—Cystitis—Methotrexate—germ cell cancer	0.000706	0.00421	CcSEcCtD
Afatinib—Hepatobiliary disease—Cisplatin—germ cell cancer	0.000705	0.0042	CcSEcCtD
Afatinib—LCK—lymph node—germ cell cancer	0.000705	0.00436	CbGeAlD
Afatinib—Mediastinal disorder—Ifosfamide—germ cell cancer	0.0007	0.00417	CcSEcCtD
Afatinib—Cough—Bleomycin—germ cell cancer	0.00069	0.00411	CcSEcCtD
Afatinib—Pneumonia—Etoposide—germ cell cancer	0.000687	0.00409	CcSEcCtD
Afatinib—Alopecia—Ifosfamide—germ cell cancer	0.000686	0.00409	CcSEcCtD
Afatinib—Infestation—Etoposide—germ cell cancer	0.000683	0.00407	CcSEcCtD
Afatinib—Infestation NOS—Etoposide—germ cell cancer	0.000683	0.00407	CcSEcCtD
Afatinib—Mental disorder—Ifosfamide—germ cell cancer	0.00068	0.00405	CcSEcCtD
Afatinib—Malnutrition—Ifosfamide—germ cell cancer	0.000676	0.00403	CcSEcCtD
Afatinib—ABL1—adrenal gland—germ cell cancer	0.000675	0.00417	CbGeAlD
Afatinib—Renal failure—Etoposide—germ cell cancer	0.000672	0.004	CcSEcCtD
Afatinib—ABL1—midbrain—germ cell cancer	0.000666	0.00412	CbGeAlD
Afatinib—Stomatitis—Etoposide—germ cell cancer	0.000666	0.00397	CcSEcCtD
Afatinib—Decreased appetite—Vinblastine—germ cell cancer	0.000664	0.00396	CcSEcCtD
Afatinib—Mouth ulceration—Methotrexate—germ cell cancer	0.000661	0.00394	CcSEcCtD
Afatinib—Bladder pain—Methotrexate—germ cell cancer	0.000661	0.00394	CcSEcCtD
Afatinib—Urinary tract disorder—Cisplatin—germ cell cancer	0.000661	0.00394	CcSEcCtD
Afatinib—Connective tissue disorder—Cisplatin—germ cell cancer	0.000658	0.00392	CcSEcCtD
Afatinib—Urethral disorder—Cisplatin—germ cell cancer	0.000656	0.00391	CcSEcCtD
Afatinib—Constipation—Vinblastine—germ cell cancer	0.000654	0.00389	CcSEcCtD
Afatinib—ABL1—bone marrow—germ cell cancer	0.000653	0.00404	CbGeAlD
Afatinib—ABL1—spinal cord—germ cell cancer	0.00065	0.00402	CbGeAlD
Afatinib—Hepatobiliary disease—Etoposide—germ cell cancer	0.000646	0.00385	CcSEcCtD
Afatinib—Infection—Bleomycin—germ cell cancer	0.000641	0.00382	CcSEcCtD
Afatinib—Sepsis—Methotrexate—germ cell cancer	0.000635	0.00378	CcSEcCtD
Afatinib—ABL1—female gonad—germ cell cancer	0.000629	0.00389	CbGeAlD
Afatinib—Eye disorder—Cisplatin—germ cell cancer	0.000626	0.00373	CcSEcCtD
Afatinib—Urinary tract disorder—Etoposide—germ cell cancer	0.000606	0.00361	CcSEcCtD
Afatinib—Mediastinal disorder—Cisplatin—germ cell cancer	0.000603	0.0036	CcSEcCtD
Afatinib—Urethral disorder—Etoposide—germ cell cancer	0.000601	0.00358	CcSEcCtD
Afatinib—Infection—Dactinomycin—germ cell cancer	0.000598	0.00356	CcSEcCtD
Afatinib—ABCB1—blood vessel—germ cell cancer	0.000595	0.00368	CbGeAlD
Afatinib—Alopecia—Cisplatin—germ cell cancer	0.000592	0.00353	CcSEcCtD
Afatinib—Cough—Ifosfamide—germ cell cancer	0.00059	0.00351	CcSEcCtD
Afatinib—ABL1—endocrine gland—germ cell cancer	0.000585	0.00362	CbGeAlD
Afatinib—ABCG2—telencephalon—germ cell cancer	0.000585	0.00362	CbGeAlD
Afatinib—Malnutrition—Cisplatin—germ cell cancer	0.000583	0.00347	CcSEcCtD
Afatinib—ABL1—head—germ cell cancer	0.000578	0.00357	CbGeAlD
Afatinib—Dyspnoea—Bleomycin—germ cell cancer	0.000575	0.00343	CcSEcCtD
Afatinib—Eye disorder—Etoposide—germ cell cancer	0.000573	0.00342	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.000571	0.00341	CcSEcCtD
Afatinib—Decreased appetite—Bleomycin—germ cell cancer	0.000561	0.00334	CcSEcCtD
Afatinib—Muscle spasms—Cisplatin—germ cell cancer	0.00056	0.00334	CcSEcCtD
Afatinib—ABL1—testis—germ cell cancer	0.000558	0.00345	CbGeAlD
Afatinib—ABCG2—decidua—germ cell cancer	0.000555	0.00343	CbGeAlD
Afatinib—Mediastinal disorder—Etoposide—germ cell cancer	0.000553	0.00329	CcSEcCtD
Afatinib—Asthenia—Vinblastine—germ cell cancer	0.000548	0.00327	CcSEcCtD
Afatinib—Infection—Ifosfamide—germ cell cancer	0.000548	0.00327	CcSEcCtD
Afatinib—Alopecia—Etoposide—germ cell cancer	0.000542	0.00323	CcSEcCtD
Afatinib—Nervous system disorder—Ifosfamide—germ cell cancer	0.000541	0.00322	CcSEcCtD
Afatinib—Skin disorder—Ifosfamide—germ cell cancer	0.000536	0.00319	CcSEcCtD
Afatinib—Decreased appetite—Dactinomycin—germ cell cancer	0.000523	0.00312	CcSEcCtD
Afatinib—Diarrhoea—Vinblastine—germ cell cancer	0.000523	0.00312	CcSEcCtD
Afatinib—Dysgeusia—Etoposide—germ cell cancer	0.000523	0.00312	CcSEcCtD
Afatinib—Fatigue—Dactinomycin—germ cell cancer	0.000519	0.00309	CcSEcCtD
Afatinib—Back pain—Etoposide—germ cell cancer	0.000516	0.00308	CcSEcCtD
Afatinib—ABL1—cerebellum—germ cell cancer	0.000516	0.00319	CbGeAlD
Afatinib—Muscle spasms—Etoposide—germ cell cancer	0.000513	0.00306	CcSEcCtD
Afatinib—Body temperature increased—Bleomycin—germ cell cancer	0.00051	0.00304	CcSEcCtD
Afatinib—Dizziness—Vinblastine—germ cell cancer	0.000505	0.00301	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.000493	0.00294	CcSEcCtD
Afatinib—Dyspnoea—Ifosfamide—germ cell cancer	0.000492	0.00293	CcSEcCtD
Afatinib—Vomiting—Vinblastine—germ cell cancer	0.000486	0.0029	CcSEcCtD
Afatinib—ABCG2—uterus—germ cell cancer	0.000485	0.003	CbGeAlD
Afatinib—Decreased appetite—Ifosfamide—germ cell cancer	0.00048	0.00286	CcSEcCtD
Afatinib—Headache—Vinblastine—germ cell cancer	0.000479	0.00285	CcSEcCtD
Afatinib—ABCG2—pituitary gland—germ cell cancer	0.000477	0.00295	CbGeAlD
Afatinib—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.000476	0.00284	CcSEcCtD
Afatinib—Body temperature increased—Dactinomycin—germ cell cancer	0.000476	0.00284	CcSEcCtD
Afatinib—Fatigue—Ifosfamide—germ cell cancer	0.000476	0.00283	CcSEcCtD
Afatinib—Infection—Cisplatin—germ cell cancer	0.000472	0.00282	CcSEcCtD
Afatinib—Constipation—Ifosfamide—germ cell cancer	0.000472	0.00281	CcSEcCtD
Afatinib—Nervous system disorder—Cisplatin—germ cell cancer	0.000466	0.00278	CcSEcCtD
Afatinib—Cough—Etoposide—germ cell cancer	0.000466	0.00278	CcSEcCtD
Afatinib—Asthenia—Bleomycin—germ cell cancer	0.000463	0.00276	CcSEcCtD
Afatinib—Skin disorder—Cisplatin—germ cell cancer	0.000462	0.00275	CcSEcCtD
Afatinib—ABCG2—medulla oblongata—germ cell cancer	0.00046	0.00284	CbGeAlD
Afatinib—Pruritus—Bleomycin—germ cell cancer	0.000457	0.00272	CcSEcCtD
Afatinib—Nausea—Vinblastine—germ cell cancer	0.000454	0.00271	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	0.000451	0.00269	CcSEcCtD
Afatinib—Body temperature increased—Ifosfamide—germ cell cancer	0.000436	0.0026	CcSEcCtD
Afatinib—Infection—Etoposide—germ cell cancer	0.000433	0.00258	CcSEcCtD
Afatinib—Asthenia—Dactinomycin—germ cell cancer	0.000432	0.00257	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—germ cell cancer	0.000427	0.00254	CcSEcCtD
Afatinib—ABCG2—adrenal gland—germ cell cancer	0.000426	0.00263	CbGeAlD
Afatinib—Dyspnoea—Cisplatin—germ cell cancer	0.000424	0.00253	CcSEcCtD
Afatinib—Skin disorder—Etoposide—germ cell cancer	0.000423	0.00252	CcSEcCtD
Afatinib—ABCG2—midbrain—germ cell cancer	0.00042	0.0026	CbGeAlD
Afatinib—ABL1—brain—germ cell cancer	0.000419	0.00259	CbGeAlD
Afatinib—Decreased appetite—Cisplatin—germ cell cancer	0.000413	0.00246	CcSEcCtD
Afatinib—Diarrhoea—Dactinomycin—germ cell cancer	0.000412	0.00245	CcSEcCtD
Afatinib—ABCG2—bone marrow—germ cell cancer	0.000412	0.00255	CbGeAlD
Afatinib—Pneumonia—Methotrexate—germ cell cancer	0.000412	0.00245	CcSEcCtD
Afatinib—Gastrointestinal disorder—Cisplatin—germ cell cancer	0.000411	0.00245	CcSEcCtD
Afatinib—Vomiting—Bleomycin—germ cell cancer	0.00041	0.00245	CcSEcCtD
Afatinib—ABCG2—spinal cord—germ cell cancer	0.00041	0.00254	CbGeAlD
Afatinib—Infestation NOS—Methotrexate—germ cell cancer	0.000409	0.00244	CcSEcCtD
Afatinib—Infestation—Methotrexate—germ cell cancer	0.000409	0.00244	CcSEcCtD
Afatinib—Rash—Bleomycin—germ cell cancer	0.000407	0.00243	CcSEcCtD
Afatinib—Dermatitis—Bleomycin—germ cell cancer	0.000407	0.00242	CcSEcCtD
Afatinib—ABL1—lymph node—germ cell cancer	0.000405	0.0025	CbGeAlD
Afatinib—Renal failure—Methotrexate—germ cell cancer	0.000402	0.0024	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—germ cell cancer	0.000399	0.00238	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—germ cell cancer	0.000398	0.00237	CcSEcCtD
Afatinib—ABCG2—female gonad—germ cell cancer	0.000397	0.00245	CbGeAlD
Afatinib—Asthenia—Ifosfamide—germ cell cancer	0.000396	0.00236	CcSEcCtD
Afatinib—Pruritus—Ifosfamide—germ cell cancer	0.00039	0.00233	CcSEcCtD
Afatinib—Dyspnoea—Etoposide—germ cell cancer	0.000388	0.00231	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—germ cell cancer	0.000387	0.00231	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—germ cell cancer	0.000386	0.0023	CcSEcCtD
Afatinib—Nausea—Bleomycin—germ cell cancer	0.000383	0.00228	CcSEcCtD
Afatinib—Vomiting—Dactinomycin—germ cell cancer	0.000383	0.00228	CcSEcCtD
Afatinib—Rash—Dactinomycin—germ cell cancer	0.00038	0.00226	CcSEcCtD
Afatinib—Decreased appetite—Etoposide—germ cell cancer	0.000379	0.00226	CcSEcCtD
Afatinib—Diarrhoea—Ifosfamide—germ cell cancer	0.000377	0.00225	CcSEcCtD
Afatinib—Gastrointestinal disorder—Etoposide—germ cell cancer	0.000376	0.00224	CcSEcCtD
Afatinib—Body temperature increased—Cisplatin—germ cell cancer	0.000376	0.00224	CcSEcCtD
Afatinib—Fatigue—Etoposide—germ cell cancer	0.000376	0.00224	CcSEcCtD
Afatinib—Constipation—Etoposide—germ cell cancer	0.000373	0.00222	CcSEcCtD
Afatinib—ABCB1—trigeminal ganglion—germ cell cancer	0.000367	0.00227	CbGeAlD
Afatinib—Dizziness—Ifosfamide—germ cell cancer	0.000365	0.00217	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—germ cell cancer	0.000363	0.00216	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—germ cell cancer	0.00036	0.00215	CcSEcCtD
Afatinib—Nausea—Dactinomycin—germ cell cancer	0.000358	0.00213	CcSEcCtD
Afatinib—ABCB1—embryo—germ cell cancer	0.000355	0.00219	CbGeAlD
Afatinib—ABCG2—testis—germ cell cancer	0.000352	0.00218	CbGeAlD
Afatinib—Vomiting—Ifosfamide—germ cell cancer	0.000351	0.00209	CcSEcCtD
Afatinib—Rash—Ifosfamide—germ cell cancer	0.000348	0.00207	CcSEcCtD
Afatinib—Dermatitis—Ifosfamide—germ cell cancer	0.000347	0.00207	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—germ cell cancer	0.000344	0.00205	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—germ cell cancer	0.000343	0.00205	CcSEcCtD
Afatinib—Asthenia—Cisplatin—germ cell cancer	0.000341	0.00203	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—germ cell cancer	0.000331	0.00197	CcSEcCtD
Afatinib—Nausea—Ifosfamide—germ cell cancer	0.000328	0.00195	CcSEcCtD
Afatinib—Diarrhoea—Cisplatin—germ cell cancer	0.000325	0.00194	CcSEcCtD
Afatinib—ABCG2—cerebellum—germ cell cancer	0.000325	0.00201	CbGeAlD
Afatinib—Alopecia—Methotrexate—germ cell cancer	0.000325	0.00193	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—germ cell cancer	0.000322	0.00192	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—germ cell cancer	0.00032	0.00191	CcSEcCtD
Afatinib—ABCB1—retina—germ cell cancer	0.000314	0.00194	CbGeAlD
Afatinib—Dysgeusia—Methotrexate—germ cell cancer	0.000313	0.00187	CcSEcCtD
Afatinib—Asthenia—Etoposide—germ cell cancer	0.000313	0.00186	CcSEcCtD
Afatinib—Back pain—Methotrexate—germ cell cancer	0.000309	0.00184	CcSEcCtD
Afatinib—Pruritus—Etoposide—germ cell cancer	0.000308	0.00184	CcSEcCtD
Afatinib—Vomiting—Cisplatin—germ cell cancer	0.000302	0.0018	CcSEcCtD
Afatinib—Rash—Cisplatin—germ cell cancer	0.0003	0.00179	CcSEcCtD
Afatinib—Dermatitis—Cisplatin—germ cell cancer	0.0003	0.00179	CcSEcCtD
Afatinib—Diarrhoea—Etoposide—germ cell cancer	0.000298	0.00178	CcSEcCtD
Afatinib—ABCB1—telencephalon—germ cell cancer	0.000289	0.00178	CbGeAlD
Afatinib—Dizziness—Etoposide—germ cell cancer	0.000288	0.00172	CcSEcCtD
Afatinib—Nausea—Cisplatin—germ cell cancer	0.000282	0.00168	CcSEcCtD
Afatinib—Cough—Methotrexate—germ cell cancer	0.000279	0.00166	CcSEcCtD
Afatinib—Vomiting—Etoposide—germ cell cancer	0.000277	0.00165	CcSEcCtD
Afatinib—Rash—Etoposide—germ cell cancer	0.000275	0.00164	CcSEcCtD
Afatinib—Dermatitis—Etoposide—germ cell cancer	0.000274	0.00164	CcSEcCtD
Afatinib—ABCB1—decidua—germ cell cancer	0.000274	0.00169	CbGeAlD
Afatinib—Headache—Etoposide—germ cell cancer	0.000273	0.00163	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	0.00027	0.00161	CcSEcCtD
Afatinib—ABCG2—brain—germ cell cancer	0.000264	0.00163	CbGeAlD
Afatinib—Infection—Methotrexate—germ cell cancer	0.000259	0.00155	CcSEcCtD
Afatinib—Nausea—Etoposide—germ cell cancer	0.000259	0.00154	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—germ cell cancer	0.000256	0.00153	CcSEcCtD
Afatinib—ABCG2—lymph node—germ cell cancer	0.000255	0.00158	CbGeAlD
Afatinib—Skin disorder—Methotrexate—germ cell cancer	0.000253	0.00151	CcSEcCtD
Afatinib—ABCB1—gonad—germ cell cancer	0.000241	0.00149	CbGeAlD
Afatinib—ABCB1—uterus—germ cell cancer	0.000239	0.00148	CbGeAlD
Afatinib—Insomnia—Methotrexate—germ cell cancer	0.000236	0.00141	CcSEcCtD
Afatinib—ABCB1—pituitary gland—germ cell cancer	0.000235	0.00145	CbGeAlD
Afatinib—Dyspnoea—Methotrexate—germ cell cancer	0.000233	0.00139	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—germ cell cancer	0.00023	0.00137	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—germ cell cancer	0.000227	0.00135	CcSEcCtD
Afatinib—ABCB1—medulla oblongata—germ cell cancer	0.000227	0.0014	CbGeAlD
Afatinib—Gastrointestinal disorder—Methotrexate—germ cell cancer	0.000225	0.00134	CcSEcCtD
Afatinib—Fatigue—Methotrexate—germ cell cancer	0.000225	0.00134	CcSEcCtD
Afatinib—ABCB1—adrenal gland—germ cell cancer	0.00021	0.0013	CbGeAlD
Afatinib—ABCB1—midbrain—germ cell cancer	0.000207	0.00128	CbGeAlD
Afatinib—Body temperature increased—Methotrexate—germ cell cancer	0.000206	0.00123	CcSEcCtD
Afatinib—ABCB1—bone marrow—germ cell cancer	0.000203	0.00126	CbGeAlD
Afatinib—ABCB1—spinal cord—germ cell cancer	0.000202	0.00125	CbGeAlD
Afatinib—ABCB1—female gonad—germ cell cancer	0.000196	0.00121	CbGeAlD
Afatinib—Asthenia—Methotrexate—germ cell cancer	0.000187	0.00112	CcSEcCtD
Afatinib—Pruritus—Methotrexate—germ cell cancer	0.000185	0.0011	CcSEcCtD
Afatinib—ABCB1—endocrine gland—germ cell cancer	0.000182	0.00113	CbGeAlD
Afatinib—ABCB1—head—germ cell cancer	0.00018	0.00111	CbGeAlD
Afatinib—Diarrhoea—Methotrexate—germ cell cancer	0.000179	0.00106	CcSEcCtD
Afatinib—ABCB1—testis—germ cell cancer	0.000174	0.00107	CbGeAlD
Afatinib—Dizziness—Methotrexate—germ cell cancer	0.000173	0.00103	CcSEcCtD
Afatinib—Vomiting—Methotrexate—germ cell cancer	0.000166	0.000989	CcSEcCtD
Afatinib—Rash—Methotrexate—germ cell cancer	0.000165	0.000981	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—germ cell cancer	0.000164	0.00098	CcSEcCtD
Afatinib—Headache—Methotrexate—germ cell cancer	0.000163	0.000974	CcSEcCtD
Afatinib—ABCB1—cerebellum—germ cell cancer	0.00016	0.000991	CbGeAlD
Afatinib—Nausea—Methotrexate—germ cell cancer	0.000155	0.000924	CcSEcCtD
Afatinib—ABCB1—brain—germ cell cancer	0.00013	0.000805	CbGeAlD
Afatinib—ABCB1—lymph node—germ cell cancer	0.000126	0.000778	CbGeAlD
Afatinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—germ cell cancer	0.000102	0.000461	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—KIT—germ cell cancer	0.000102	0.000459	CbGpPWpGaD
Afatinib—ERBB2—Disease—FGF4—germ cell cancer	0.000102	0.000458	CbGpPWpGaD
Afatinib—DYRK1A—Cell Cycle—TP53—germ cell cancer	0.000101	0.000457	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—MYC—germ cell cancer	0.000101	0.000452	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—KIT—germ cell cancer	0.0001	0.000452	CbGpPWpGaD
Afatinib—ERBB4—Disease—FGF4—germ cell cancer	0.0001	0.000451	CbGpPWpGaD
Afatinib—ABL1—Immune System—PVRL2—germ cell cancer	9.88e-05	0.000445	CbGpPWpGaD
Afatinib—ABL1—DNA Damage Response (only ATM dependent)—HRAS—germ cell cancer	9.84e-05	0.000443	CbGpPWpGaD
Afatinib—EPHA6—Axon guidance—HRAS—germ cell cancer	9.84e-05	0.000443	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—FGFR3—germ cell cancer	9.8e-05	0.000441	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—KIT—germ cell cancer	9.66e-05	0.000435	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—MYC—germ cell cancer	9.66e-05	0.000435	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—FGFR3—germ cell cancer	9.44e-05	0.000425	CbGpPWpGaD
Afatinib—LCK—PDGFR-beta signaling pathway—MYC—germ cell cancer	9.25e-05	0.000416	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—FGF4—germ cell cancer	9.15e-05	0.000412	CbGpPWpGaD
Afatinib—ERBB2—Disease—H2AFZ—germ cell cancer	9.09e-05	0.000409	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KITLG—germ cell cancer	9.06e-05	0.000408	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—KIT—germ cell cancer	9e-05	0.000405	CbGpPWpGaD
Afatinib—ERBB4—Disease—H2AFZ—germ cell cancer	8.96e-05	0.000403	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KITLG—germ cell cancer	8.92e-05	0.000402	CbGpPWpGaD
Afatinib—LCK—B Cell Receptor Signaling Pathway—HRAS—germ cell cancer	8.9e-05	0.000401	CbGpPWpGaD
Afatinib—ABL1—PDGFR-beta signaling pathway—HRAS—germ cell cancer	8.82e-05	0.000397	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—FGF4—germ cell cancer	8.82e-05	0.000397	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KITLG—germ cell cancer	8.8e-05	0.000396	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—FGF4—germ cell cancer	8.79e-05	0.000396	CbGpPWpGaD
Afatinib—LCK—Cell surface interactions at the vascular wall—HRAS—germ cell cancer	8.76e-05	0.000394	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—KIT—germ cell cancer	8.67e-05	0.00039	CbGpPWpGaD
Afatinib—EGFR—ErbB1 downstream signaling—HRAS—germ cell cancer	8.67e-05	0.00039	CbGpPWpGaD
Afatinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—germ cell cancer	8.62e-05	0.000388	CbGpPWpGaD
Afatinib—BLK—Immune System—KITLG—germ cell cancer	8.59e-05	0.000386	CbGpPWpGaD
Afatinib—EGFR—Disease—SLC2A3—germ cell cancer	8.57e-05	0.000386	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—FGF4—germ cell cancer	8.47e-05	0.000381	CbGpPWpGaD
Afatinib—EGFR—Immune System—PVRL2—germ cell cancer	8.44e-05	0.00038	CbGpPWpGaD
Afatinib—ERBB2—Disease—KITLG—germ cell cancer	8.37e-05	0.000377	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—FGFR3—germ cell cancer	8.36e-05	0.000376	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—OXT—germ cell cancer	8.35e-05	0.000376	CbGpPWpGaD
Afatinib—LCK—Disease—SLC2A3—germ cell cancer	8.26e-05	0.000372	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—TP53—germ cell cancer	8.25e-05	0.000372	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—MYC—germ cell cancer	8.25e-05	0.000371	CbGpPWpGaD
Afatinib—ERBB4—Disease—KITLG—germ cell cancer	8.24e-05	0.000371	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—OXT—germ cell cancer	8.23e-05	0.00037	CbGpPWpGaD
Afatinib—LCK—Signaling by Interleukins—HRAS—germ cell cancer	8.17e-05	0.000368	CbGpPWpGaD
Afatinib—LCK—Immune System—PVRL2—germ cell cancer	8.13e-05	0.000366	CbGpPWpGaD
Afatinib—ERBB2—Signaling by NGF—HRAS—germ cell cancer	8.04e-05	0.000362	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	8e-05	0.00036	CbGpPWpGaD
Afatinib—IRAK1—Immune System—FGF4—germ cell cancer	7.97e-05	0.000359	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—TP53—germ cell cancer	7.93e-05	0.000357	CbGpPWpGaD
Afatinib—ERBB4—Signaling by NGF—HRAS—germ cell cancer	7.92e-05	0.000357	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	7.73e-05	0.000348	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—KIT—germ cell cancer	7.67e-05	0.000345	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	7.62e-05	0.000343	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—MYC—germ cell cancer	7.58e-05	0.000341	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KITLG—germ cell cancer	7.52e-05	0.000339	CbGpPWpGaD
Afatinib—ERBB2—Axon guidance—HRAS—germ cell cancer	7.28e-05	0.000328	CbGpPWpGaD
Afatinib—LCK—PDGFR-beta signaling pathway—HRAS—germ cell cancer	7.27e-05	0.000327	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KITLG—germ cell cancer	7.25e-05	0.000326	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KITLG—germ cell cancer	7.22e-05	0.000325	CbGpPWpGaD
Afatinib—EGFR—Direct p53 effectors—TP53—germ cell cancer	7.2e-05	0.000324	CbGpPWpGaD
Afatinib—ABL1—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	7.17e-05	0.000323	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—FGF4—germ cell cancer	7.13e-05	0.000321	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—FGF4—germ cell cancer	7.02e-05	0.000316	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—HRAS—germ cell cancer	7.02e-05	0.000316	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KITLG—germ cell cancer	6.96e-05	0.000313	CbGpPWpGaD
Afatinib—EGFR—Signaling by SCF-KIT—HRAS—germ cell cancer	6.85e-05	0.000308	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	6.84e-05	0.000308	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—OXT—germ cell cancer	6.84e-05	0.000308	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—TP53—germ cell cancer	6.78e-05	0.000305	CbGpPWpGaD
Afatinib—ERBB2—Immune System—FGFR3—germ cell cancer	6.73e-05	0.000303	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—SLC2A3—germ cell cancer	6.7e-05	0.000302	CbGpPWpGaD
Afatinib—ERBB4—Immune System—FGFR3—germ cell cancer	6.63e-05	0.000299	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—SLC22A3—germ cell cancer	6.6e-05	0.000297	CbGpPWpGaD
Afatinib—ABCG2—Transmembrane transport of small molecules—AVP—germ cell cancer	6.6e-05	0.000297	CbGpPWpGaD
Afatinib—LCK—Signaling by SCF-KIT—HRAS—germ cell cancer	6.6e-05	0.000297	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	6.57e-05	0.000296	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling of activated FGFR—HRAS—germ cell cancer	6.55e-05	0.000295	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KITLG—germ cell cancer	6.55e-05	0.000295	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—FGFR3—germ cell cancer	6.54e-05	0.000294	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB4—HRAS—germ cell cancer	6.45e-05	0.00029	CbGpPWpGaD
Afatinib—BLK—Immune System—FGFR3—germ cell cancer	6.38e-05	0.000287	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—H2AFZ—germ cell cancer	6.37e-05	0.000287	CbGpPWpGaD
Afatinib—PHKG2—Disease—MYC—germ cell cancer	6.34e-05	0.000285	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—HRAS—germ cell cancer	6.31e-05	0.000284	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—H2AFZ—germ cell cancer	6.27e-05	0.000282	CbGpPWpGaD
Afatinib—ABL1—Immune System—FGF4—germ cell cancer	6.24e-05	0.000281	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TP53—germ cell cancer	6.22e-05	0.00028	CbGpPWpGaD
Afatinib—ERBB2—Disease—FGFR3—germ cell cancer	6.22e-05	0.00028	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—HRAS—germ cell cancer	6.21e-05	0.00028	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KIT—germ cell cancer	6.18e-05	0.000278	CbGpPWpGaD
Afatinib—EGFR—Downstream signal transduction—HRAS—germ cell cancer	6.16e-05	0.000277	CbGpPWpGaD
Afatinib—EGFR—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	6.13e-05	0.000276	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR—HRAS—germ cell cancer	6.13e-05	0.000276	CbGpPWpGaD
Afatinib—ERBB4—Disease—FGFR3—germ cell cancer	6.12e-05	0.000276	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—HRAS—germ cell cancer	6.1e-05	0.000274	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KIT—germ cell cancer	6.09e-05	0.000274	CbGpPWpGaD
Afatinib—EGFR—DAP12 signaling—HRAS—germ cell cancer	6.07e-05	0.000273	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—OXT—germ cell cancer	6.04e-05	0.000272	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KIT—germ cell cancer	6.01e-05	0.00027	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	5.98e-05	0.000269	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—HRAS—germ cell cancer	5.93e-05	0.000267	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—HRAS—germ cell cancer	5.91e-05	0.000266	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—HRAS—germ cell cancer	5.9e-05	0.000266	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—HRAS—germ cell cancer	5.88e-05	0.000264	CbGpPWpGaD
Afatinib—BLK—Immune System—KIT—germ cell cancer	5.86e-05	0.000264	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KITLG—germ cell cancer	5.86e-05	0.000264	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—HRAS—germ cell cancer	5.85e-05	0.000263	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—HRAS—germ cell cancer	5.81e-05	0.000262	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KITLG—germ cell cancer	5.77e-05	0.00026	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	5.76e-05	0.000259	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AVP—germ cell cancer	5.73e-05	0.000258	CbGpPWpGaD
Afatinib—ERBB2—Disease—KIT—germ cell cancer	5.71e-05	0.000257	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—HRAS—germ cell cancer	5.71e-05	0.000257	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—HRAS—germ cell cancer	5.71e-05	0.000257	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	5.71e-05	0.000257	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—HRAS—germ cell cancer	5.66e-05	0.000255	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AVP—germ cell cancer	5.64e-05	0.000254	CbGpPWpGaD
Afatinib—ERBB4—Disease—KIT—germ cell cancer	5.62e-05	0.000253	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	5.62e-05	0.000253	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—HRAS—germ cell cancer	5.61e-05	0.000252	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—FGFR3—germ cell cancer	5.59e-05	0.000252	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—HRAS—germ cell cancer	5.58e-05	0.000251	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—HRAS—germ cell cancer	5.5e-05	0.000248	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	5.5e-05	0.000248	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—HRAS—germ cell cancer	5.5e-05	0.000248	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—HRAS—germ cell cancer	5.45e-05	0.000245	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—HRAS—germ cell cancer	5.4e-05	0.000243	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—HRAS—germ cell cancer	5.39e-05	0.000243	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—FGFR3—germ cell cancer	5.39e-05	0.000242	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CRABP1—germ cell cancer	5.38e-05	0.000242	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—HRAS—germ cell cancer	5.38e-05	0.000242	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—FGFR3—germ cell cancer	5.37e-05	0.000242	CbGpPWpGaD
Afatinib—EGFR—Immune System—FGF4—germ cell cancer	5.33e-05	0.00024	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—HRAS—germ cell cancer	5.28e-05	0.000238	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—HRAS—germ cell cancer	5.19e-05	0.000234	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—FGFR3—germ cell cancer	5.17e-05	0.000233	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FGF4—germ cell cancer	5.16e-05	0.000232	CbGpPWpGaD
Afatinib—LCK—Immune System—FGF4—germ cell cancer	5.14e-05	0.000231	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KIT—germ cell cancer	5.13e-05	0.000231	CbGpPWpGaD
Afatinib—ABL1—Immune System—KITLG—germ cell cancer	5.13e-05	0.000231	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—HRAS—germ cell cancer	5.09e-05	0.000229	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	5.06e-05	0.000228	CbGpPWpGaD
Afatinib—PHKG2—Disease—HRAS—germ cell cancer	4.98e-05	0.000224	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KIT—germ cell cancer	4.95e-05	0.000223	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KIT—germ cell cancer	4.93e-05	0.000222	CbGpPWpGaD
Afatinib—EGFR—Disease—FGF4—germ cell cancer	4.92e-05	0.000222	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—germ cell cancer	4.89e-05	0.00022	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	4.87e-05	0.000219	CbGpPWpGaD
Afatinib—IRAK1—Immune System—FGFR3—germ cell cancer	4.87e-05	0.000219	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KIT—germ cell cancer	4.75e-05	0.000214	CbGpPWpGaD
Afatinib—LCK—Disease—FGF4—germ cell cancer	4.74e-05	0.000214	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AVP—germ cell cancer	4.69e-05	0.000211	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—H2AFZ—germ cell cancer	4.6e-05	0.000207	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—HRAS—germ cell cancer	4.59e-05	0.000206	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—HRAS—germ cell cancer	4.52e-05	0.000203	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KIT—germ cell cancer	4.47e-05	0.000201	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HRAS—germ cell cancer	4.41e-05	0.000198	CbGpPWpGaD
Afatinib—EGFR—Disease—H2AFZ—germ cell cancer	4.4e-05	0.000198	CbGpPWpGaD
Afatinib—EGFR—Immune System—KITLG—germ cell cancer	4.38e-05	0.000197	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—FGFR3—germ cell cancer	4.35e-05	0.000196	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HRAS—germ cell cancer	4.34e-05	0.000195	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—FGFR3—germ cell cancer	4.29e-05	0.000193	CbGpPWpGaD
Afatinib—LCK—Disease—H2AFZ—germ cell cancer	4.24e-05	0.000191	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KITLG—germ cell cancer	4.24e-05	0.000191	CbGpPWpGaD
Afatinib—LCK—Immune System—KITLG—germ cell cancer	4.22e-05	0.00019	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HRAS—germ cell cancer	4.17e-05	0.000188	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AVP—germ cell cancer	4.14e-05	0.000186	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—HRAS—germ cell cancer	4.12e-05	0.000185	CbGpPWpGaD
Afatinib—EGFR—Disease—KITLG—germ cell cancer	4.04e-05	0.000182	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—OXT—germ cell cancer	4.04e-05	0.000182	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KIT—germ cell cancer	4e-05	0.00018	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KIT—germ cell cancer	3.94e-05	0.000177	CbGpPWpGaD
Afatinib—LCK—Disease—KITLG—germ cell cancer	3.9e-05	0.000175	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—OXT—germ cell cancer	3.89e-05	0.000175	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—HRAS—germ cell cancer	3.89e-05	0.000175	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HRAS—germ cell cancer	3.81e-05	0.000172	CbGpPWpGaD
Afatinib—ABL1—Immune System—FGFR3—germ cell cancer	3.81e-05	0.000171	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—HRAS—germ cell cancer	3.75e-05	0.000169	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC2A3—germ cell cancer	3.62e-05	0.000163	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC22A3—germ cell cancer	3.57e-05	0.000161	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—AVP—germ cell cancer	3.57e-05	0.000161	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—HRAS—germ cell cancer	3.52e-05	0.000158	CbGpPWpGaD
Afatinib—ABL1—Immune System—KIT—germ cell cancer	3.5e-05	0.000157	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	3.45e-05	0.000155	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGF4—germ cell cancer	3.45e-05	0.000155	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGF4—germ cell cancer	3.32e-05	0.00015	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HRAS—germ cell cancer	3.32e-05	0.000149	CbGpPWpGaD
Afatinib—EGFR—Immune System—FGFR3—germ cell cancer	3.26e-05	0.000147	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FGFR3—germ cell cancer	3.15e-05	0.000142	CbGpPWpGaD
Afatinib—ERBB2—Disease—MYC—germ cell cancer	3.14e-05	0.000141	CbGpPWpGaD
Afatinib—LCK—Immune System—FGFR3—germ cell cancer	3.14e-05	0.000141	CbGpPWpGaD
Afatinib—ERBB4—Disease—MYC—germ cell cancer	3.09e-05	0.000139	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—H2AFZ—germ cell cancer	3.08e-05	0.000139	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—germ cell cancer	3.01e-05	0.000136	CbGpPWpGaD
Afatinib—EGFR—Disease—FGFR3—germ cell cancer	3.01e-05	0.000135	CbGpPWpGaD
Afatinib—EGFR—Immune System—KIT—germ cell cancer	2.99e-05	0.000135	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—H2AFZ—germ cell cancer	2.97e-05	0.000134	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—HRAS—germ cell cancer	2.94e-05	0.000132	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CRABP1—germ cell cancer	2.91e-05	0.000131	CbGpPWpGaD
Afatinib—LCK—Disease—FGFR3—germ cell cancer	2.9e-05	0.00013	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KIT—germ cell cancer	2.89e-05	0.00013	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—HRAS—germ cell cancer	2.88e-05	0.00013	CbGpPWpGaD
Afatinib—LCK—Immune System—KIT—germ cell cancer	2.88e-05	0.00013	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	2.83e-05	0.000128	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KITLG—germ cell cancer	2.83e-05	0.000127	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AVP—germ cell cancer	2.77e-05	0.000125	CbGpPWpGaD
Afatinib—EGFR—Disease—KIT—germ cell cancer	2.76e-05	0.000124	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KITLG—germ cell cancer	2.73e-05	0.000123	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HRAS—germ cell cancer	2.67e-05	0.00012	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AVP—germ cell cancer	2.67e-05	0.00012	CbGpPWpGaD
Afatinib—LCK—Disease—KIT—germ cell cancer	2.66e-05	0.00012	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—germ cell cancer	2.63e-05	0.000118	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—germ cell cancer	2.6e-05	0.000117	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—germ cell cancer	2.53e-05	0.000114	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—germ cell cancer	2.51e-05	0.000113	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—germ cell cancer	2.48e-05	0.000112	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—germ cell cancer	2.47e-05	0.000111	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—germ cell cancer	2.43e-05	0.000109	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—germ cell cancer	2.37e-05	0.000107	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—germ cell cancer	2.22e-05	9.98e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—germ cell cancer	2.2e-05	9.9e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—germ cell cancer	2.17e-05	9.75e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—germ cell cancer	2.14e-05	9.62e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—germ cell cancer	2.13e-05	9.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGFR3—germ cell cancer	2.1e-05	9.47e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—germ cell cancer	2.05e-05	9.24e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGFR3—germ cell cancer	2.03e-05	9.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KIT—germ cell cancer	1.93e-05	8.7e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—germ cell cancer	1.93e-05	8.7e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KIT—germ cell cancer	1.86e-05	8.38e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—germ cell cancer	1.81e-05	8.13e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—germ cell cancer	1.78e-05	8.01e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—germ cell cancer	1.73e-05	7.78e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—germ cell cancer	1.7e-05	7.66e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—germ cell cancer	1.59e-05	7.16e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—germ cell cancer	1.52e-05	6.84e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—germ cell cancer	1.51e-05	6.8e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—germ cell cancer	1.46e-05	6.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—germ cell cancer	1.41e-05	6.36e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—germ cell cancer	1.31e-05	5.88e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—germ cell cancer	1.29e-05	5.81e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—germ cell cancer	1.25e-05	5.62e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—germ cell cancer	1.24e-05	5.6e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—germ cell cancer	1.19e-05	5.37e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—germ cell cancer	1.15e-05	5.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—germ cell cancer	1.06e-05	4.79e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—germ cell cancer	1.02e-05	4.61e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—germ cell cancer	8.73e-06	3.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—germ cell cancer	8.42e-06	3.79e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—germ cell cancer	8.35e-06	3.76e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—germ cell cancer	8.05e-06	3.62e-05	CbGpPWpGaD
